Exclusive financial advisor to Hitachi High-Tech Corporation
KPMG Corporate Finance LLC acted as exclusive financial advisor to Hitachi High-Tech Corporation
KPMG Corporate Finance LLC and KPMG FAS Co., Ltd. acted as exclusive investment banking advisor to Hitachi High-Tech Corporation (Hitachi High-Tech or HHT) on its strategic investment in Invivoscribe, Inc. (IVS), a global provider of blood cancer testing kits and services. In addition to cross-border investment banking advisory services, KPMG LLP also provided financial due diligence and tax due diligence services thereby providing a fully integrated and multidisciplinary solution for HHT.
"Invivoscribe is excited by the synergistic opportunities, combining our core expertise in global standardization of tests and bioinformatics, our clinical lab services, and our processes for developing custom companion diagnostics from analytical/clinical validations through international regulatory approvals and commercialization, with Hitachi’s expertise in instrumentation development and manufacturing,” said Jeffrey Miller, CEO and founder of Invivoscribe.
About Hitachi High-Tech
Hitachi High-Tech, headquartered in Tokyo, Japan, is engaged in activities in a broad range of fields, including the manufacture and sales of clinical analyzers, biotechnology products, analytical instruments, semiconductor manufacturing equipment, and analysis equipment, and providing high value-added solutions in the fields of social and industrial infrastructures and mobility. HHT’s consolidated revenues for FY 2021 were approximately USD 5.1 billion.
Invivoscribe has been improving lives with Precision Diagnostics for more than twenty-five years, advancing the field of precision medicine by developing and selling standardized reagents, tests, and bioinformatics tools to more than 700 customers in 160 countries. Invivoscribe is engaged in three core business functions: 1) testing services for blood cancers, 2) global sales and distribution of test kits and licensing bioinformatics software, and 3) the development and commercialization of companion diagnostics to support pharmaceutical approval of new oncology treatments.
KPMG Corporate Finance
The global Corporate Finance practice of KPMG International’s network of independent member firms was ranked as the top (#1) M&A middle-market adviser globally by Refinitiv, based on number of completed transactions, for the past 20 years.
Trust KPMG Corporate Finance LLC with your next transaction.